Evidence map›Paper›PMID 37895970›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Verubulin (Azixa) Analogues with Increased Saturation: Synthesis, SAR and Encapsulation in Biocompatible Nanocontainers Based on Ca

Kseniya N Sedenkova, Denis N Leschukov, Yuri K Grishin, Nikolay A Zefirov, Yulia A Gracheva, Dmitry A Skvortsov, Yanislav S Hrytseniuk, Lilja A Vasilyeva, Elena A Spirkova, Pavel N Shevtsov and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Kseniya N SedenkovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-0294-9581
Denis N LeschukovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Yuri K GrishinDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Nikolay A ZefirovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Yulia A GrachevaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Dmitry A SkvortsovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Yanislav S HrytseniukDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Lilja A VasilyevaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena A SpirkovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), 142432 Chernogolovka, Russia.
Pavel N ShevtsovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), 142432 Chernogolovka, Russia.
Elena F ShevtsovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), 142432 Chernogolovka, Russia.ORCID 0000-0003-2887-1185
Alina R LukmanovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Vasily V SpiridonovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Alina A MarkovaEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.
Minh T NguyenEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0002-4185-5844
Alexander A ShtilDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Olga N ZefirovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Alexander A YaroslavovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena R MilaevaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena B AverinaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-6107-2003
Lomonosov Moscow State University · RUInstitute of Physiologically Active Compounds · RUInstitute of Biochemical Physics NM Emanuel · RU

Funding

Ministry of Science and Higher Education of the Russian Federation Agreement with Zelinsky Institute of Organic Chemistry RAS No 075-15-2020-803RF State Program for IBCP RAS Project №122041400114-2Russian Science Foundation 22-14-00099
6 · The paper itself

Abstract

Tubulin-targeting agents attract undiminished attention as promising compounds for the design of anti-cancer drugs. Verubulin is a potent tubulin polymerization inhibitor, binding to colchicine-binding sites. In the present work, a series of verubulin analogues containing a cyclohexane or cycloheptane ring 1,2-annulated with pyrimidine moiety and various substituents in positions 2 and 4 of pyrimidine were obtained and their cytotoxicity towards cancer and non-cancerous cell lines was estimated. The investigated compounds revealed activity against various cancer cell lines with IC

Indexed as

apoptosis induceraromatic nucleophilic substitutioncross-linked alginatenanocontainerpyrimidinetetrahydroquinazolinetubulin polymerization inhibitorverubulin

Identifiers

PMID37895970
PMCPMC10610134
OpenAlexW4387843891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.